Microba Launches $5M Raise to Fund Path to Break-Even by 2027
Microba launches $5 million capital raise to fund path to cashflow break-even
Microba Life Sciences has launched a $5.0 million placement at $0.05 per share, with commitments secured from existing and new institutional and sophisticated investors. Strategic partner Sonic Healthcare (ASX: SHL) is investing $1.5 million as part of the placement. The raise, combined with streamlined and AI-enhanced operations, delivers the path to whole company cashflow break-even in CY2027 on a run-rate basis.
Eligible shareholders can participate in a $1.0 million Share Purchase Plan (SPP) at the same $0.05 offer price, with applications up to $30,000 per shareholder. The placement price represents a 20.6% discount to the last close of $0.063 and a 25.3% discount to the 5-day VWAP of $0.067.
Participants in both the placement and SPP will receive one free attaching option for every one new share subscribed, exercisable at $0.0625 and expiring three years from the issue date. All attaching options are subject to shareholder approval at a General Meeting scheduled for 24 July 2026.
When big ASX news breaks, our subscribers know first
What is gut microbiome testing?
The gut microbiome refers to the trillions of bacteria, fungi, and other microorganisms living in the human digestive system. These microorganisms play a critical role in digestion, immune function, and overall health. When the balance of these microorganisms is disrupted, it can contribute to gastrointestinal disorders, metabolic conditions, and other health issues.
Microba’s diagnostic testing analyses a patient’s gut microbiome to help clinicians understand the composition and function of these microorganisms. This information enables healthcare professionals to make more informed treatment decisions, identify potential health risks, and monitor patient responses to interventions. The company operates at the intersection of diagnostics and therapeutics, two high-growth healthcare sectors, with technology that transforms complex microbiome data into actionable clinical insights.
11 consecutive quarters of core testing sales growth
Microba has reported 11 consecutive quarters of total core testing sales growth, demonstrating sustained commercial traction. The company recorded 106% growth in last 12 months core testing sales, comparing the latest four quarters to the prior four.
Adoption in Australia is increasingly driven by enterprise-style healthcare clinic contracts, which provide a more scalable and predictable revenue base. Growth in the United Kingdom continues to outperform Australia at the equivalent time post-launch, leveraging the acquired Invivo0 base.
In Q3 CY26, Microba is set to launch a new category-defining testing product, which is positioned as a catalyst for the next phase of Diagnostics growth with mainstream medical professionals.
Key growth metrics:
- 11 consecutive quarters of total core testing sales growth
- 106% growth in last 12 months core testing sales (latest 4 quarters vs prior 4)
- Q3 CY26 new product launch timeline
- UK growth outperforming Australia at equivalent post-launch stage
How Microba plans to reach break-even in CY2027
The company is forecast to deliver break-even for the whole company in CY2027 on a run-rate basis. Current monthly cash burn is approximately $1.3 million.
The break-even pathway consists of two components: a ~$700,000 reduction from streamlined operations with cost reductions and multiple leveraged AI-efficiencies, and a ~$600,000 increase per month through revenue and margin growth, leveraging a fixed cost base.
Operational efficiencies already in place
Microba has built infrastructure that is already delivering measurable efficiencies across the business:
- Sales & marketing: AI-supported customer targeting, unified global brand, automated lifecycle marketing, and self-serve sign-up reducing customer acquisition cost
- Cost reductions: AI automation across customer support, HR, legal, and finance structurally lowers cost to serve as Microba scales
- Engineering, science & product: Major new product build about to complete, with AI-supported product, evidence, and software development systems cutting engineering and product cost per release
- Sales growth & margin expansion: Rising volume on fixed cost base with margin expansion from pricing power, scaling economics, and operational efficiency
Therapeutics division positioned for partnering
The Therapeutics platform and asset portfolio is described as world-class, including Phase 2-ready MAP 315. The division is active in a partnering process with a Boston-based specialist adviser. Recent positive clinical trial readouts for the sector provide a favourable backdrop for these discussions.
The therapeutics assets represent potential upside optionality beyond the core diagnostics business, with partnering activity already underway.
Recent corporate interest validates company value
Following an approach to Microba by a UK-based Private Equity fund, the company engaged in extensive due diligence and agreed terms on an in-principle basis (subject to conditions including shareholder approval) for the divestment of Microba’s Diagnostics and Supplements businesses.
The consideration would have exceeded the market capitalisation of Microba, which was based on a $44 million market cap on 28 April 2026. The company chose not to proceed when the final deal structure was no longer in the best interest of shareholders.
Placement and SPP structure
The placement will be conducted in two tranches. Tranche 1 will result in the issue of 91,344,455 shares under the company’s existing 15% placement capacity, settling on 17 June 2026. Tranche 2 will result in the issue of 8,659,785 shares, subject to shareholder approval at the General Meeting on 24 July 2026.
All attaching options (both Tranche 1 and Tranche 2) will be issued subject to shareholder approval at the General Meeting for the purpose of ASX Listing Rule 7.1.
Proceeds raised under the placement will be used to deliver core diagnostics growth across Australia and the UK, delivery of the category-defining new testing product, strengthening working capital, and costs of the offer. SPP proceeds will be used for working capital requirements.
| Term | Placement | SPP |
|---|---|---|
| Offer Price | $0.05 | $0.05 |
| Amount | $5.0 million | Up to $1.0 million |
| Attaching Options | 1:1 @ $0.0625 | 1:1 @ $0.0625 |
| Approval | Tranche 1 existing capacity; Tranche 2 shareholder approval | Shareholder approval |
Chair outlines strategic positioning
Pasquale Rombola, Chair
“This funding positions us to achieve group cashflow break-even on a run-rate basis in 2027 whilst continuing to accelerate core Diagnostics growth, delivery of a major new test release in Q3 CY26, and progress to partner our Therapeutic assets. We are building a category-defining company with world-leading technology to transform the lives of millions of patients suffering from gastrointestinal disorders.”
The next major ASX story will hit our subscribers first
Key dates for investors
- Record Date for SPP: 7:00pm AEST, 11 June 2026
- Settlement of Tranche 1: 17 June 2026
- Allotment of Tranche 1 Shares: 18 June 2026
- Prospectus lodgement: 19 June 2026
- Offer Opening Date: 22 July 2026
- Offer Closing Date: 24 July 2026
- General Meeting: 27 July 2026
- Tranche 2 allotment: 29 July 2026
These dates provide actionable milestones for shareholders considering SPP participation. The company has noted that the timetable is indicative and may be subject to change without notice, subject to the Corporations Act, ASX Listing Rules, and other applicable laws.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Get real-time alerts on capital raises, clinical trial results, and regulatory approvals before the market moves. Click the “Free Alerts” button at Big News Blast to start receiving notifications the moment news breaks.